Background and Objectives: The aim of this study is to evaluate relation among on inflammation markers, lipid profile, diastolic function and endothelial function and the effects of atrovastatin on these parameters in patients with angina pectoris. Methods: This study included 46 patients (55.5짹10.6 years, 29 males) with angiographically diagnosed coronary heart disease (CAD) who were treated with atorvastatin (10 mg for 6 months). Inflammatory markers measured by white blood cell (WBC) counts, monocyte counts, high-sensitivity C-reactive protein (hs-CRP) and von Willebrand factor (VWF). Diastolic function measured by echocardiography. Endothelial function measured by flow-mediated dilation (FMD) at brachial artery with nitroglycerin-mediated dilation (NMD) and lipid profile. These parameters were compared baseline and 6 months after atorvastatin administration. Results: VWF, NMD and diastolic function were unchanged. WBC counts significantly decreased from 7.05 짹1.6 ��103/mm3 to 6.31 짹1.4 ��103/mm3 (p=0.010). Monocyte counts significantly decreased from 0.51 짹0.2 ��103/mm3 to 0.43 ��0.1/mm3 짹 1.4 (p=0.032). The level of hs-CPR significantly decreased from 0.34 짹0.76 mg/dL to 0.15 짹0.4 mg/dL (p=0.009) ant that of total cholesterol (TC) level was significantly decreased from 181.2짹39.7 mg/dL to 143.9짹57.2 mg/dL (p<0.001). The low density lipoprotein cholesterol (LDL-C) significantly decreased from 123.7짹37.2 mg/dL to 85.0짹27.7 mg/dL (p<0.001). The FMD was significantly increased from 5.9짹2.1% to 7.0짹2.9% (p=0.014). Conclusion: Therapy of atorvastatin decreased the inflammatory markers, TC and LDL-C, and improved FMD in patients with stable angina.